Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Metastatic
•
HER+
What is your treatment approach in a male with ER+ Her2+ metastatic breast cancer who received TCHP but developed irreversible cardiomyopathy?
Related Questions
What are your top takeaways in Breast Cancer from ASCO 2024?
In what circumstance, if any, would you consider fulvestrant + capivasertib over CDK4/6 inhibitors in a patient who has HR+, PIK3CA mutant metastatic breast cancer?
How would you approach a patient with metastatic high grade neuroendocrine carcinoma of the breast which is HR+ HER2 negative?
Would you offer local therapy with either SBRT or Y-90 in a patient with metastatic ER+ HER2 low breast cancer with two oligometastatic liver lesions currently on AI + CDK4/6 inhibitor?
For patients with ER-negative HER2-ultralow breast cancer, how and when would you incorporate T-DXd?
How are you requesting testing for HER2-ultralow status, in light of DB-06 trial demonstrating benefit of T-DXd for these patients?
In what situations would you consider doublet chemotherapy in treatment of a premenopausal de novo metastatic TNBC?
How do you monitor blood glucose levels in patients without preexisting diabetes who are starting capivasertib?
Is there a correlation with severity of rash as an adverse event and response rate with capivasertib?
Do you use breast MRI or ultrasound to assess tumor size prior to neoadjuvant chemotherapy in breast cancer?
